Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)
Publication date
2024-01
Authors
van Dorp, Jeroen
Pipinikas, Christodoulos
Suelmann, B. B.M.
Mehra, Niven
van Dijk, Nick
Marsico, Giovanni
van Montfoort, Maurits L
Hackinger, Sophie
Braaf, Linde M
Amarante, Tauanne
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
cc_by
Abstract
Correction to: Nature Medicine. Published online 2 February 2023. In the version of this article initially published, the first name of Antoine G. van der Heijden was misspelled as “Toine” and has now been corrected in the HTML and PDF versions of the article.
Keywords
General Biochemistry,Genetics and Molecular Biology, Published Erratum
Citation
van Dorp, J, Pipinikas, C, Suelmann, B B M, Mehra, N, van Dijk, N, Marsico, G, van Montfoort, M L, Hackinger, S, Braaf, L M, Amarante, T, van Steenis, C, McLay, K, Daletzakis, A, van den Broek, D, van de Kamp, M W, Hendricksen, K, de Feijter, J M, Boellaard, T N, Meijer, R P, van der Heijden, A G, Rosenfeld, N, van Rhijn, B W G, Jones, G & van der Heijden, M S 2024, 'Author Correction : High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)', Nature Medicine, vol. 30, no. 1, pp. 304. https://doi.org/10.1038/s41591-023-02500-7